1-苯并[b]噻吩-3-基-2-氯乙酮 | 26167-44-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 1-苯并[b]噻吩-3-基-2-氯乙酮
• 中文别名: 3-氯乙酰苯并[B]噻吩
• 英文名称: 3-Chloracetyl-benzothiophen
• 英文别名: 3-Chloroacetylbenzo-[b]thiophene；3-Chloroacetylbenzo[b]thiophene；1-(1-benzothiophen-3-yl)-2-chloroethanone
• CAS: 26167-44-2
• 化学式: C₁₀H₇ClOS
• 分子量: 210.684
• InChiKey: OTWORIPHJRKXBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  3-乙酰硫茚	3-acetylbenzothiophene	1128-05-8	C10H8OS	176.239

反应信息

• 作为反应物：
  描述：

  1-苯并[b]噻吩-3-基-2-氯乙酮 在 盐酸 、 potassium carbonate 、 potassium iodide 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 8.0h， 生成 N1-benzyl-N4-[2-carbonyl-2-(benzo[b]thiophene-3-yl)]ethylpiperazine hydrochloride
  参考文献：
  名称：

  BENZOTHIOPHENE ALKANOL PIPERAZINE DERIVATIVES AND THEIR USE AS ANTIDEPRESSANT

  摘要：

  公开号：

  EP2311828B9
• 作为产物：
  描述：

  3-乙酰硫茚 在 四氯化碳 、 氯仿 、 氯 作用下， 生成 1-苯并[b]噻吩-3-基-2-氯乙酮
  参考文献：
  名称：

  4-(3'-Thianaphthyl)-2-mercaptothiazole

  摘要：

  DOI：

  10.1021/ja01148a516

文献信息

• [EN] 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS<br/>[FR] DERIVES DE 1-(2H-PYRAZOL-3-YL)-3-{4-`1-(BENZOYL)-PIPERIDIN-4-YLMETHYL!-PHENYL}-UREE ET COMPOSES ASSOCIES UTILISES COMME INHIBITEURS DE LA KINASE P38 ET/OU COMME INHIBITEURS DU FACTEUR DE NECROSE TUMORALE (TNF) DANS LE TRAITEMENT DES INFLAMMATIONS
  申请人：AVENTIS PHARMA INC

  公开号：WO2004100946A1

  公开（公告）日：2004-11-25

  The present invention provides compounds of Formula (I) Wherein ( ) is an optional ethylene bridge; R1 is alkyl, cycloalkyl, aryl or aryl substituted with one or more substituents selected from alkyl, alkoxy and amino, or R1 is pyridyl or pyridyl substituted with one or more substituents selected from alkyl, alkoxy and amino; R2 is optionally substituted alkyl, alkoxyalkyl, optionally substituted cycloalkylalkyl, arylalkyl, or R2 is arylalkyl substituted with one or more substituents selected from alkyl, alkoxy; X is -C(O)-, -C(O)-CH2-, -S(O)2-, or NH-C(O)- ; and A is optionally substituted alkyl or other substituents as defined in claim 1. Pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF), such as asthma or joint inflammation.

  本发明提供了Formula (I)的化合物，其中( )是可选的乙烯桥；R1是烷基、环烷基、芳基或芳基，其上取代基可为烷基、烷氧基和氨基中的一种或多种，或者R1是吡啶基或吡啶基，其上取代基可为烷基、烷氧基和氨基中的一种或多种；R2是可选取代的烷基、烷氧基烷基、可选取代的环烷基烷基、芳基烷基，或者R2是芳基烷基，其上取代基可为烷基、烷氧基中的一种或多种；X是-C(O)-、-C(O)-CH2-、-S(O)2-或NH-C(O)-；A是可选取代的烷基或其他在权利要求1中定义的取代基。包括这些化合物的药物组合物、其制备以及在治疗能够通过抑制p38激酶和/或肿瘤坏死因子(TNF)调节的疾病状态中的药用，如哮喘或关节炎。
• Benzo(b)thiophene derivatives and process for producing the same
  申请人：——

  公开号：US20030176490A1

  公开（公告）日：2003-09-18

  The present invention is 3,4-disubstituted-benzo[b]thiophene derivatives represented by general formula (I) and processes for preparing compounds represented by general formula (V) from compounds represented by general formula (IV), preparing a mixture of compounds represented by the following formula (II) and the following formula (III) and preparing the benzo[b]thiophene derivatives represented by the above formula (I). 1 wherein, R 1 and R 2 represent each a halogen atom, a trihalomethyl group, a C 1-4 alkyl group or a C 14 alkoxy group; X represents a hydroxy group or a halogen atom; R 3 and R 4 represent each a hydrogen or a halogen atom, a trihalomethyl group, a C 1-4 alkyl group or a C 1-4 alkoxy group; and R 5 represents a C 1-3 alkyl group or a trifluoromethyl group.

  本发明涉及一种由通式（I）表示的3,4-二取代苯并[b]噻吩衍生物以及从通式（IV）表示的化合物制备通式（V）表示的化合物的过程，制备以下式（II）和以下式（III）表示的化合物的混合物，并制备上述通式（I）表示的苯并[b]噻吩衍生物。其中，R1和R2分别表示卤原子、三卤甲基基团、C1-4烷基基团或C14烷氧基团；X表示羟基或卤原子；R3和R4分别表示氢原子或卤原子、三卤甲基基团、C1-4烷基基团或C1-4烷氧基团；R5表示C1-3烷基基团或三氟甲基基团。
• [EN] PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS<br/>[FR] INHIBITEURS DE LA BIOSYNTHESE DE LA PROSTAGLANDINE ENDOPEROXYDE H SYNTHASE
  申请人：ABBOTT LAB

  公开号：WO2000024719A1

  公开（公告）日：2000-05-04

  The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important 'housekeeping' enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

  本发明描述了式（I）的吡啶酮化合物，它们是环氧合酶（COX）抑制剂，特别是选择性抑制剂环氧合酶-2（COX-2）。COX-2是与炎症有关的诱导型同工酶，而非构成型同工酶环氧合酶-1（COX-1），后者是许多组织（包括胃肠道和肾脏）中重要的“管家”酶。这些化合物对COX-2的选择性最小化了目前市场上非甾体类抗炎药（NSAIDs）所见的不良胃肠道和肾脏副作用。
• Prostaglandin endoperoxide H synthase biosynthesis inhibitors
  申请人：——

  公开号：US20020013318A1

  公开（公告）日：2002-01-31

  The present invention describes pyridazinone compounds of formula I 1 which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

  本发明描述了一类式I1的吡啶嗪化合物，它们是环氧合酶（COX）抑制剂，特别是选择性抑制剂环氧合酶-2（COX-2）。COX-2是与炎症相关的可诱导异构体，而不是重要的“家政”酶在许多组织中，包括胃肠道（GI）和肾脏中的构成性异构体环氧合酶-1（COX-1）。这些化合物对COX-2的选择性最小化了目前市场上非甾体抗炎药（NSAIDs）所见到的不良的GI和肾脏副作用。
• Pyrazoles as inhibitors of tumor necrosis factor
  申请人：Borcherding R. David

  公开号：US20060063796A1

  公开（公告）日：2006-03-23

  The present invention provides compounds of Formula (I) and ester prodrugs, pharmaceutically acceptable salts or solvates of such compounds; or ester prodrugs of such salts or solvates; pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF).

  本发明提供了式（I）的化合物和酯前药、这些化合物的药学上可接受的盐或溶剂；或这些盐或溶剂的酯前药；包括这些化合物的制药组合物，其制备以及它们在治疗能够通过抑制p38激酶和/或肿瘤坏死因子（TNF）调节的疾病状态中的药物应用。